Analytical Data
-
Gene name
IL-9
- Application
-
Alternative Names
IL-9, T-cell growth factor P40
-
Species
Mouse
-
Source
E. coli
-
Tag
Tag Free
-
Purity
>97% as determined by SDS-PAGE
-
Uniprot
P15247
-
Expression Region
Gln19~Pro144
-
Molecular Weight
14.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-9 (IL-9) is a cytokine mainly produced by T-helper 2 cells and is known for its role in promoting inflammation and modulating immune responses. Research into IL-9 has gained momentum due to its involvement in various allergic and inflammatory diseases, including asthma, atopic dermatitis, and rheumatoid arthritis. IL-9 operates through the IL-9 receptor (IL-9R), influencing a range of immune cells, such as mast cells, eosinophils, and T cells, thereby enhancing the production of other cytokines and contributing to the pathophysiology of allergic reactions. As a result, IL-9 and its signaling pathway have become potential therapeutic targets for treating allergic diseases and other immune disorders. The production of recombinant IL-9 protein has enabled researchers to investigate its biological functions, mechanisms of action, and the development of IL-9 antagonists or therapies that could ameliorate the effects of excessive IL-9 signaling. Current studies focus on exploring how IL-9 and its receptor interact with various immune cells, the molecular pathways involved in IL-9-mediated inflammation, and the potential of utilizing recombinant IL-9 or its inhibitors in clinical settings. This research not only aims to deepen the understanding of IL-9's role in immune regulation but also to pave the way for innovative treatments that can alleviate the burden of chronic inflammatory diseases associated with IL-9 dysregulation.
